Nektar Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul '26 Jul 22, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Cap	2,342	862	173	108	426	2,506
Market Cap Growth	661.39%	398.70%	59.68%	-74.61%	-82.99%	-18.16%
Enterprise Value	1,754	701.62	20.11	-77.64	52.66	1,915
Last Close Price	69.32	42.28	13.95	8.48	33.90	202.65
Forward PE	-	15.88	15.88	15.88	15.88	15.88
PS Ratio	42.10	15.60	1.76	1.20	4.63	24.59
PB Ratio	3.55	9.59	2.84	0.83	1.16	3.69
P/TBV Ratio	2.35	7.94	3.15	0.82	1.46	4.11
EV/Sales Ratio	31.53	12.70	0.20	-0.86	0.57	18.79
EV/EBITDA Ratio	-	-	-	0.30	-	-
EV/EBIT Ratio	-	-	-	0.29	-	-
EV/FCF Ratio	-	-	-	0.40	-	-
Debt / Equity Ratio	0.11	0.73	1.36	0.75	0.31	0.19
Net Debt / Equity Ratio	-0.84	-1.78	-2.51	-1.42	-1.02	-0.87
Net Debt / EBITDA Ratio	3.63	1.15	1.51	0.73	1.03	1.37
Net Debt / FCF Ratio	2.38	0.77	0.86	0.96	1.21	1.38
Asset Turnover	0.11	0.19	0.28	0.16	0.10	0.08
Inventory Turnover	-	-	3.81	1.91	1.24	1.60
Quick Ratio	9.85	4.59	4.16	5.95	7.49	8.88
Current Ratio	10.21	4.97	4.26	6.45	8.00	9.34
Return on Equity (ROE)	-45.67%	-206.35%	-124.10%	-110.95%	-70.39%	-59.64%
Return on Assets (ROA)	-25.78%	-47.92%	-29.92%	-47.53%	-41.52%	-33.63%
Return on Invested Capital (ROIC)	-1305.60%	-	-	-	-926.84%	-351.06%
Return on Capital Employed (ROCE)	-28.88%	-59.70%	-35.71%	-53.31%	-44.93%	-36.34%
Buyback Yield / Dilution	-39.76%	-23.05%	-8.24%	-1.53%	-2.09%	-2.64%
Total Shareholder Return	-39.76%	-23.05%	-8.24%	-1.53%	-2.09%	-2.64%

SEC Filings: 10-K · 10-Q